{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-385331","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2026-09-08T20:54:32+00:00","discovered_at":"2026-09-08T20:56:03.761694+00:00","generated_at":"2026-09-08T20:56:14.413354+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Amylyx enters avexitide supply agreements with Bachem and Polypeptide; $30M upfront to Polypeptide","bullets":["Paid or agreed $30M upfront fee to Polypeptide for capacity reservation under term sheet.","Bachem Manufacturing Agreement begins 2028 with minimum annual purchase quantities of avexitide drug substance.","Both suppliers are non-exclusive; Amylyx may use alternate manufacturers.","Supply prices adjusted annually for labor, utilities, overhead; terms auto-renew after 5 years.","Agreements cover commercial manufacturing of avexitide if regulatory approval is obtained."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-385331","json":"https://secwatch.observer/filing/0001193125-26-385331.json","markdown":"https://secwatch.observer/filing/0001193125-26-385331.md","text":"https://secwatch.observer/filing/0001193125-26-385331.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526385331/0001193125-26-385331-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526385331/d160615d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T20:56:14.413354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}